AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 282 min read$LFCR

Lifecore Biomedical To Be Taken Private By Webster Equity Partners In Up To $663.7 Mln Deal

Lifecore Biomedical (LFCR) agreed to be acquired by Webster Equity Partners for up to $663.7 million. The deal offers $6.28 per share plus a CVR, representing a 49.5% premium. The transaction, expected to close in Q4 2026, requires shareholder and regulatory approvals. Lifecore's stock will be delisted post-closing.

Original reporting
rttnews.com
Published Sep 28, 2026, 1:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Lifecore Biomedical To Be Taken Private By Webster Equity Partners In Up To $663.7 Mln Deal — source image
Source · rttnews.com
Decision brief

The 30-second read

$LFCRBullishHigh
01

Why it matters

The cash offer represents a significant premium, likely driving LFCR shares up to the offer price while the pending delisting creates a short‑term trading catalyst.

02

Market read

First disclosure of a $663.7 M M&A deal, creating immediate price impact for LFCR and signaling continued private‑equity interest in the biotech space.

03

What to watch

Potential antitrust or regulatory hurdles could delay or block the transaction.

Relevance 9/10Novelty 9/10Timing: today

Background

Webster Equity Partners secured financing from MidCap Financial Trust, MSD Partners, and Alcon Research to fund the acquisition.

Company-level read

Ticker impact

$LFCRBullishHigh confidence
Context

Lifecore Biomedical announced a definitive agreement to be taken private by Webster Equity Partners for up to $663.7 million, a cash premium of ~49.5% and a potential 130% premium with CVR payments.

Expected impact

likely upward pressure as the market prices in the cash premium and CVR upside

Evidence & confidence

First‑report of a mid‑cap M&A transaction with a $6.28 per share cash offer and potential $9.67 per share consideration creates immediate valuation upside.

Market effects

Sector

Consolidation trend in the biomedical device sector may pressure peers' valuations.

Regional

Midwest biotech market sees increased M&A activity perception.

Global

Adds to overall private‑equity driven buy‑outs in US healthcare, modest global impact.

Counterpoint

What could challenge this read

If the CVR milestones are not met, the effective purchase price could fall, creating downside risk.

Key entities

  • Company
    Lifecore Biomedical, Inc.

    Target of the acquisition, ticker LFCR, Nasdaq-listed.

  • Private Equity Firm
    Webster Equity Partners

    Acquirer, providing cash and CVR consideration.

Read at source← All news

Also covered by

1 outlet

Related articles

AUG 12
$LFCRMedAI 8/10

Lifecore Biomedical (LFCR) Q2 2026 Earnings Call Transcript

Lifecore Biomedical (LFCR) reported Q2 2026 revenue of $34.2M, down 6.2% year over year, and a net loss of $6.2M ($0.19/share). Adjusted EBITDA was $8.6M. Gross margin fell to 35.3%. The company reaffirmed 2026 revenue guidance of $120M to $125M and adjusted EBITDA guidance of $20.5M to $25M, citing a 2027 demand inflection tied to Japanese market approval.

fool.com6 min
AUG 5
$LFCRMed

Lifecore Biomedical, Inc.: Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update

Lifecore Biomedical (NASDAQ: LFCR) reported Q2 2026 revenues of $34.2M, down 6.2% year over year, and net loss of $6.2M ($0.19 per diluted share). Six-month revenues fell to $57.4M. Gross profit declined, while liquidity was about $38.8M. The company signed six new programs in Q2, added 13 over 12 months, and reaffirmed 2026 guidance.

finanznachrichten.de6 min
AUG 5
$LFCRMed

LIFECORE BIOMEDICAL, INC. \DE\ (LFCR): Results of Operations and Financial Condition

LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026 , and Provides Corporate Update -- Reaffirms 2026 Guidance -- -- Multiple New Business Wins, Adding Impactful Programs to Pipeline -- -- Cost Reduction and Productivity Enhanceme

SEC EDGAR 8-K6 min
SEP 29
$SMMTHighAI 9/10

Summit Therapeutics agrees to US$2B AZN investment

Summit Therapeutics (SMMT) announced a US$2B investment from AstraZeneca (AZN) via convertible preferred shares at US$18.36 per common-share equivalent, an 18.6% premium. The deal, expected to close by Oct. 2, will fund cancer drug development, including ivonescimab. AstraZeneca will own about 12% of Summit's outstanding common shares post-investment.

mugglehead.com2 min